Clinical Trial of Quantitative Detection Kit for Hsp90α in Hepatic Cancer

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02324127

Enrollment

1100

Registered

2014-12-24

Start date

2012-10-31

Completion date

2014-12-31

Last updated

2014-12-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Cancer

Brief summary

Detect plasma Hsp90α concentration of liver cancer patients, healthy volunteers, benign liver diseases.

Detailed description

Detect plasma Hsp90α concentration of liver cancer patients, healthy volunteers, benign liver diseases, validate accuracy, specificity and sensitivity of Hsp90α kit.

Interventions

DEVICEhsp90

Detect plasma Hsp90α concentration of lung cancer patients

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Yes

Inclusion criteria

* Liver cancer patients * Healthy volunteers, * Benign liver diseases patients

Exclusion criteria

* Patients who Previously accepted radiotherapy

Design outcomes

Primary

Measure	Time frame	Description
Hsp90α Concentration of plasma	4 months	Detect Hsp90α Concentration(ng/ml) of plasma and calculate the accuracy, specificity and sensitivity of Hsp90α kit

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 26, 2026